Dt&바카라사이트 벳무브 provides global non-clinical advanced 바카라사이트 벳무브 services with a focus on ophthalmic diseases

[by Ji, Yong Jun] Dt&바카라사이트 벳무브 announced on May 7 that it is providing global-standard services by leveraging a standardized efficacy evaluation system and advanced analysis capabilities, under the leadership of a study director with extensive expertise in non-clinical ophthalmic disease research.

The company is a full-service clinical trial contract research organization (바카라사이트 벳무브) that provides comprehensive support a바카라사이트 벳무브ss the entire drug development process, encompassing non-clinical trial analysis, bioequivalence testing, clinical trials, and licensing consulting. Dt&바카라사이트 벳무브 delivers integrated solutions to facilitate full-cycle new drug development for Korean and international pharmaceutical and biotechnology companies. In particular, the company generates global-standard test data, drawing on its specialized expertise in efficacy testing, toxicity evaluation, and PK/PD analysis.

The company operates a range of 바카라사이트 벳무브 disease models, including dry and wet macular degeneration, optic nerve damage, dry eye, and glaucoma, and is characterized by its ability to overcome the technical challenges associated with tissue processing in rodent-based retinal disease models.

“Our goal is to broaden the depth and scope of non-clinical efficacy testing a바카라사이트 벳무브ss a range of therapeutic areas, including ophthalmic diseases,” a DT&바카라사이트 벳무브 official said. “We are committed to reinforcing our role as a trusted partner in novel drug development by providing customized test designs and data analysis.”